These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18040264)

  • 1. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F; Heiduschka P; Schraermeyer U;
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision.
    Sørensen TL; Kemp H
    Acta Ophthalmol; 2011 Feb; 89(1):e97. PubMed ID: 20384603
    [No Abstract]   [Full Text] [Related]  

  • 4. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I; Zografos L; Ambresin A
    Ophthalmologica; 2008; 222(5):321-3. PubMed ID: 18617755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
    Ahlers C; Golbaz I; Stock G; Fous A; Kolar S; Pruente C; Schmidt-Erfurth U
    Ophthalmology; 2008 Aug; 115(8):e39-46. PubMed ID: 18675694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes.
    Raja MS; Saldana M; Goldsmith C; Burton BJ
    Br J Ophthalmol; 2010 Nov; 94(11):1543-5. PubMed ID: 20516142
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
    Keane PA; Chang KT; Liakopoulos S; Jivrajka RV; Walsh AC; Sadda SR
    Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
    Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for age-related macular degeneration.
    Patel S
    Retina; 2009 Jun; 29(6 Suppl):S45-8. PubMed ID: 19553801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avastin and new treatments for AMD: where are we?
    Freeman WR; Falkenstein I
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract]   [Full Text] [Related]  

  • 17. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration.
    McKibbin M; Papastefanou V; Matthews B; Cook H; Downey L
    Eye (Lond); 2010 Jun; 24(6):994-8. PubMed ID: 19911016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
    Figurska M; Robaszkiewicz J; Wierzbowska J
    Klin Oczna; 2010; 112(4-6):147-50. PubMed ID: 20825071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.